Department of Biomedical molecular biology, University of Ulm, London School of Hygiene & Tropical Medicine, Friedrich-Loeffler-Institut, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, GlaxoSmithKline (Belgium), Yonsei University, University of Cape Town, ETH Zurich, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Max Planck Society, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo, Oxford University Museum of Natural History, Aston University, Statens Serum Institut, Paul Ehrlich Institut, Institut Pasteur, Stellenbosch University, University Hospital of Lausanne, University of Basel, Aeras, Pasteur Institute of Lille, University of Sydney, University of Geneva, Istituto Superiore di Sanità , Université Libre de Bruxelles, Transgene (France), Medical Research Council, University College Dublin, University of Lausanne, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Imperial College London, Leiden University Medical Center, TuBerculosis Vaccine Initiative, University of KwaZulu-Natal, University of Strathclyde, Bangor University, French National Centre for Scientific Research, Department of Health and Social Care, International Tuberculosis Research Center, Department for Environment Food and Rural Affairs, University of Zurich, UK Research and Innovation, Biomedical Primate Research Centre, University of Zaragoza, Institut Scientifique de Santé Publique, Sciensano (Belgium)
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Expressions of Interest (EoI) prior to this ...